Aegerion Pharmaceuticals Announces Presentation at the Cowen and Company 33rd Annual Health Care Conference CAMBRIDGE, Mass., Feb. 27, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (Nasdaq:AEGR), an emerging biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating and often fatal rare diseases, announced today that the company will participate in the Cowen and Company 33rd Annual Health Care Conference in Boston. Marc Beer, Chief Executive Officer of Aegerion, is scheduled to present on Monday, March 4, 2013 at 1:30 p.m. ET. The presentation will be webcast live and may be accessed for up to 14 days following the conference by visiting the "Investors" section of Aegerion's website, www.aegerion.com. About Aegerion Pharmaceuticals Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative, life-altering therapies for patients with debilitating, often fatal, rare diseases. For more information about the company, please visit www.aegerion.com. The Aegerion Pharmaceuticals, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=16441 CONTACT: Aegerion Pharmaceuticals, Inc. Amanda Murphy Manager, Investor Relations 857-242-5024 Aegerion Pharmaceuticals, Inc. Logo
Aegerion Pharmaceuticals Announces Presentation at the Cowen and Company 33rd Annual Health Care Conference
Press spacebar to pause and continue. Press esc to stop.